Literature DB >> 8406826

Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.

G S Pfrommer1, S M Dickens, M A Wilson, B J Young, T R Kozel.   

Abstract

Incubation of encapsulated and nonencapsulated Cryptococcus neoformans in normal human serum (NHS) leads to activation and binding of potentially opsonic fragments of complement component C3 to the yeast cells. Analysis of the molecular forms of C3 after incubation of encapsulated cryptococci in NHS showed that the percentage of bound C3 occurring as iC3b approached 100% after 8 min. The percentage of bound C3 occurring as iC3b on nonencapsulated cryptococci never exceeded 70%, even after 60 min of incubation in NHS. Conversion of C3b to iC3b was assessed further by incubating C3b-coated cryptococci for various times with a mixture of complement factors H and I at 40% of their respective physiological concentrations. Most, if not all, of the C3b on encapsulated cryptococci was converted to iC3b at a single fast rate. Conversion of C3b to iC3b on nonencapsulated cryptococci did not follow a single rate constant and appeared to have a fast and a slow component. Studies of the requirements for factors H and I in cleavage of C3b to iC3b showed steep dose-response curves for both factors in the case of encapsulated cryptococci and shallow curves with C3b bound to nonencapsulated cryptococci. Taken together, our results indicate that C3b molecules bound to encapsulated cryptococci have a uniformly high susceptibility to conversion to iC3b by factors H and I. In contrast, a significant portion of the C3b bound to nonencapsulated cryptococci is very resistant to conversion to iC3b by factors H and I.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406826      PMCID: PMC281167          DOI: 10.1128/iai.61.10.4360-4366.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

4.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

5.  Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.

Authors:  T R Kozel; G S Pfrommer
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Species specificity of recognition by the alternative pathway of complement.

Authors:  R D Horstmann; M K Pangburn; H J Müller-Eberhard
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

7.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

8.  Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin.

Authors:  S M Levitz; A Tabuni
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

10.  Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.

Authors:  M K Pangburn; R D Schreiber; J S Trombold; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  11 in total

1.  Complement receptor 3 binds the Borrelia burgdorferi outer surface proteins OspA and OspB in an iC3b-independent manner.

Authors:  Rodolfo C Garcia; Rossella Murgia; Marina Cinco
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Binding of Cryptococcus neoformans to heterologously expressed human complement receptors.

Authors:  S M Levitz; A Tabuni; T R Kozel; R S MacGill; R R Ingalls; D T Golenbock
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.

Authors:  S Merino; X Rubires; A Aguilar; S Albertí; S Hernandez-Allés; V J Benedí; J M Tomas
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 4.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

5.  Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Authors:  Thomas R Kozel; Stuart M Levitz; Françoise Dromer; Marcellene A Gates; Peter Thorkildson; Guilhem Janbon
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans.

Authors:  M X Zhang; D M Lupan; T R Kozel
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.

Authors:  M X Zhang; B Klein
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 8.  Activation of the complement system by pathogenic fungi.

Authors:  T R Kozel
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

Review 9.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 10.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.